Arylguanidine and arylbiguanide binding at 5-HT3 serotonin receptors: A QSAR study

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 20, 2003, Pages 4449-4454

  Glennon, Richard A ^a   Daoud, Maha Khalifa ^a   Dukat, Małgorzata ^a   Teitler, Milt ^b   Herrick Davis, Katharine ^b   Purohit, Anil ^b   Syed, Hasan ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBIGUANIDE; ARYLGUANIDINE; BIGUANIDE DERIVATIVE; GUANIDINE DERIVATIVE; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; ELECTRON; LIPOPHILICITY; MOLECULAR DYNAMICS; MOLECULE; POLARIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY;

EID: 0041833669     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00488-7     Document Type: Article

References (23)

1. Glennon, R. A.; Dukat, M.; Westkaemper, R.B. In Watson, S. J., Ed. Psychopharmacology, A Generation of Progress; Lippincott-Raven: New York, 1998 (CD ROM version).
2. 3 receptors. In Olivier B, van Wijngaarden I, Soudin, W. Eds, Serotonin Receptors and Their Ligands; Elsevier: Amsterdam, 1997; p 221.
3. King, F. D.; Jones, B. J.; Sanger, G. J., Eds. 5-Hydroxytryptamine-3 Receptor Antagonists; CRC: Boca Raton, FL, 1994.
4. Kilpatrick G. J., Butler A., Burridge J., Oxford W. Eur. J. Pharmacol. 182:1990;193.
5. Glennon R. A., Ismaiel A. M., McCarthy B. G., Peroutka S. J. Eur. J. Pharmacol. 168:1989;387.
6. Campiani G., Cappelli A., Nacci V., Anzini M., Vomero S., Hamon M., Cagnotto A., Fracasso C., Uboldi C., Caccia S., Consolo S., Mennini T. J. Med. Chem. 40:1997;3670.
7. Ito H., Kiso T., Miyata K., Kamato T., Yuki H., Akuzawa S., Nagakura Y., Yamano M., Susuki M., Naitoh Y., Sakai H., Iwaoka K., Yamaguchi T. Eur. J. Pharmacol. 409:2000;195.
8. Sato Y., Yamada M., Yoshida S., Soneda T., Ishikawa M., Nizato T., Suzuki K., Konno F. J. Med. Chem. 41:1998;3015.
9. Daveu C., Bureau R., Baglin I., Prunier H., Lancelot J.-C., Rault S. J. Chem. Inf. Comput. Sci. 39:1999;362.
10. Cappelli A., Anzini M., Vomero S., Mennuni L., Makovec F., Hamon M., De Benedetti P. G., Menziani M. C. Cur. Topics Med. Chem. 2:2002;599.
11. Yamada M., Sato Y., Kobayashi K., Konno F., Soneda T., Watanabe T. Chem. Pharm. Bull. (Tokyo). 46:1998;445.
12. Bureau R., Daveu C., Baglin I., Sopkova-De Oliviera Santos J., Lancelot J. C., Rault S. J. Chem. Inf. Comput. Sci. 41:2001;815.
13. Dukat M., Abdel-Rahman A. A., Ismaiel A. M., Ingher S., Teitler M., Gyermek L., Glennon R. A. J. Med. Chem. 39:1996;4017.
14. Dukat M., Young R., Darmani N. N., Ahmed B., Glennon R. A. Psychopharmacology (Berlin). 150:2000;200.
15. Dukat M., Choi Y., Teitler M., Du Pre A., Herrick-Davis K., Smith C., Glennon R. A. Bioorg. Med. Chem. Lett. 11:2001;1599.
16. Verloop, A.; Hoogenstraaten, W.; Tipker, J. In Ariens, E. J., Ed., Drug Design; Academic: New York, 1976; Vol. 7, p 165.
17. Taft R. W., Topsom R. D. Progr. Phys. Org. Chem. 16:1987;1.
18. Kier L. B., Hall L. H. Molecular Connectivity in Chemistry and Drug Research. 1976;Academic, New York.
19. Morain P., Abraham C., Portevin B., DeNanteuil G. Mol. Pharmaol. 46:1994;732.
20. Smart, B. E. In Banks, R. E., Smart, B. E., Tatlow, J. C., Eds; Organofluorine Chemistry: Principles and Commercial Applications; Plenum: New York, 1994; Chapter 4, p 57.
21. King H., Tonkin I. M. J. Chem. Soc. 1946;1063.
22. Hughes J. L., Liu R. C., Enkoji T., Smith C. M., Bastian J. W., Luna P. D. J. Med. Chem. 18:1975;1077.
23. Hansch C., Leo A., Unger S. H., Kim K. H., Nikaitani D., Lien E. J. J. Med. Chem. 16:1973;1207.